Opinion|Videos|May 29, 2025
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
Advertisement
Episodes in this series
Physician Summary:
Nogapendekin Alfa Inbakicept-pmln
- Mechanism of Action: Nogapendekin alfa is an immunotherapy that combines a recombinant protein designed to stimulate the immune system with the aim of inducing a localized immune response against bladder cancer cells, particularly for carcinoma in situ and papillary tumors. It acts by enhancing the body’s immune response to cancer cells, stimulating an inflammatory response that targets the tumor. This approach helps activate the immune system without requiring systemic exposure.
- Administration: Nogapendekin alfa is administered intravesically, with patients typically receiving the therapy directly into the bladder via catheter. After intravesical administration, it is followed by a course of intravesical BCG therapy, which further primes the immune response and increases efficacy by maintaining bladder immunity over time.
This combination approach offers a novel, dual immunotherapeutic strategy for BCG-unresponsive NMIBC, potentially enhancing both local and systemic immune responses to bladder cancer.
Advertisement
Related to this article
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5